Tarceva approved in Europe for genetically distinct type of lung cancer

Tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations.

Tarceva is also indicated as monotherapy for maintenance treatment in patients with locally advanced or metastatic NSCLC with stable disease after 4 cycles of standard platinum-based first-line chemotherapy.

Tarceva is also indicated for the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen.

When prescribing Tarceva, factors associated with prolonged survival should be taken into account.

No survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC negative tumours.

Pancreatic cancer:
Tarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer. When prescribing Tarceva, factors associated with prolonged survival should be taken into account (see sections 4.2 and 5.1).

No survival advantage could be shown for patients with locally advanced disease.

(Source: European Medicines Agency)

More information

For more information on cancer, including breast, prostate, kidney and stomach cancer, see Cancer: Overview.

Related Diseases

• Pancreatic Cancer (Adenocarcinoma of the Pancreas)

Related Articles:

• Lung cancer gene identified for the first time
• Antifolates show promise against lung cancer subtype
• Epigenetic therapy shows promise in hard-to-treat lung cancer
• A new approach to lung cancer treatment
• Men: Cancer prevention tips by age
• Celecoxib may prevent lung cancer in former smokers
• Drug combination extends survival in refractory lung cancer patients
• Breakthrough in lung cancer research
• Gene information predicts survival time, possible new treatment options for lung cancer patients
• CT screening significantly reduces lung cancer mortality

Connect

Sign up for free newsletters

Subscribe to RSS feeds

Discuss on Forum

Article Comments

Rate this article